Akcea now shoot­ing for $200M-plus as a new line­up of biotech IPOs prep for a launch

Akcea Ther­a­peu­tics is up­ping the ante on its IPO.

The Io­n­is sub­sidiary orig­i­nal­ly mapped out a plan to raise $100 mil­lion in its ini­tial of­fer­ing, but in an amend­ed S-1 to­day the com­pa­ny in­creased its po­ten­tial to $155 mil­lion, with its part­ners at No­var­tis ready to pitch in with $50 mil­lion more if Akcea achieves cer­tain fi­nan­cial bench­marks with in­vestors.

Akcea spelled out plans $AK­CA to sell 9.62 mil­lion shares at $12 to $14 a share with un­der­writ­ers get­ting an op­tion on 1.4 mil­lion shares. At the midrange, that would leave Io­n­is with 73.4% of the shares.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.